Survival Between Mastectomy and Breast-Conserving Surgery in De Novo Metastatic Breast Cancer: A Propensity Score-Matched Study.

IF 3.5 4区医学 Q2 SURGERY

Journal of Investigative Surgery Pub Date : 2025-12-01 Epub Date: 2025-09-01 DOI:10.1080/08941939.2025.2550774

Yi-Yan Hong, Hong-Liang Zhan, Guan-Qiao Li, Qiu-Yan Chen, San-Gang Wu, Fu-Xing Zhang

{"title":"Survival Between Mastectomy and Breast-Conserving Surgery in De Novo Metastatic Breast Cancer: A Propensity Score-Matched Study.","authors":"Yi-Yan Hong, Hong-Liang Zhan, Guan-Qiao Li, Qiu-Yan Chen, San-Gang Wu, Fu-Xing Zhang","doi":"10.1080/08941939.2025.2550774","DOIUrl":null,"url":null,"abstract":"Purpose: To compare the outcomes between mastectomy (MAST) and breast-conserving surgery (BCS) in patients with de novo metastatic breast cancer (dnMBC).Methods: Patients diagnosed with dnMBC between 2010 and 2020 were retrospectively included. The chi-square test, binomial logistic regression, propensity score matching (PSM), Kaplan-Meier method, and multivariate Cox proportional analysis were used for statistical analyses.Results: A total of 7880 patients were identified, including 2248 (28.5%) patients who underwent BCS and 5632 (71.5%) had achieved MAST. Although no statistically significant difference was found (p = 0.182), patients receiving MAST had a decreasing trend in later years. There were 74.3% (n = 629) of patients receiving MAST in 2010 and 68.5% (n = 366) in 2020. Younger age, advanced tumor stage, and advanced nodal stage were independent predictors of receiving MAST. There were 466 pairs of patients who were completely matched using PSM. The 3-year breast cancer-specific survival (BCSS) was 72.4% and 73.0% in patients treated with BCS and MAST, respectively (p = 0.509). The 3-year overall survival (OS) was 68.4% and 70.5% in patients treated with BCS and MAST, respectively (p = 0.702). The multivariate prognostic analyses showed that MAST had a similar BCSS (p = 0.996) and OS (p = 0.784) than those in BCS group.Conclusions: Our study suggests that BCS and MAST yield similar survival outcomes in dnMBC.","PeriodicalId":16200,"journal":{"name":"Journal of Investigative Surgery","volume":"38 1","pages":"2550774"},"PeriodicalIF":3.5000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigative Surgery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08941939.2025.2550774","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To compare the outcomes between mastectomy (MAST) and breast-conserving surgery (BCS) in patients with de novo metastatic breast cancer (dnMBC).

Methods: Patients diagnosed with dnMBC between 2010 and 2020 were retrospectively included. The chi-square test, binomial logistic regression, propensity score matching (PSM), Kaplan-Meier method, and multivariate Cox proportional analysis were used for statistical analyses.

Results: A total of 7880 patients were identified, including 2248 (28.5%) patients who underwent BCS and 5632 (71.5%) had achieved MAST. Although no statistically significant difference was found (p = 0.182), patients receiving MAST had a decreasing trend in later years. There were 74.3% (n = 629) of patients receiving MAST in 2010 and 68.5% (n = 366) in 2020. Younger age, advanced tumor stage, and advanced nodal stage were independent predictors of receiving MAST. There were 466 pairs of patients who were completely matched using PSM. The 3-year breast cancer-specific survival (BCSS) was 72.4% and 73.0% in patients treated with BCS and MAST, respectively (p = 0.509). The 3-year overall survival (OS) was 68.4% and 70.5% in patients treated with BCS and MAST, respectively (p = 0.702). The multivariate prognostic analyses showed that MAST had a similar BCSS (p = 0.996) and OS (p = 0.784) than those in BCS group.

Conclusions: Our study suggests that BCS and MAST yield similar survival outcomes in dnMBC.

查看原文本刊更多论文

新发转移性乳腺癌乳房切除术和保乳手术的生存率：一项倾向评分匹配研究。

目的：比较乳房切除术（MAST）和保乳手术（BCS）治疗新发转移性乳腺癌（dnMBC）的疗效。方法：回顾性分析2010 ~ 2020年诊断为dnMBC的患者。统计学分析采用卡方检验、二项logistic回归、倾向评分匹配（PSM）、Kaplan-Meier法和多变量Cox比例分析。结果：共纳入7880例患者，其中2248例（28.5%）行BCS， 5632例（71.5%）行MAST。虽然没有统计学差异（p = 0.182），但接受MAST治疗的患者在后期有下降趋势。2010年接受MAST治疗的患者占74.3% (n = 629)， 2020年占68.5% （n = 366）。年龄小、肿瘤分期和淋巴结分期是接受MAST治疗的独立预测因素。有466对患者使用PSM完全匹配。BCS和MAST治疗的3年乳腺癌特异性生存率（BCSS）分别为72.4%和73.0% （p = 0.509）。BCS和MAST患者的3年总生存率（OS）分别为68.4%和70.5% （p = 0.702）。多因素预后分析显示，MAST组的BCSS （p = 0.996）和OS （p = 0.784）与BCS组相似。结论：我们的研究表明，BCS和MAST在dnMBC中产生相似的生存结果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Investigative Surgery 医学-外科

CiteScore

4.20

自引率

0.00%

发文量

114

审稿时长

6-12 weeks

期刊介绍： Journal of Investigative Surgery publishes peer-reviewed scientific articles for the advancement of surgery, to the ultimate benefit of patient care and rehabilitation. It is the only journal that encompasses the individual and collaborative efforts of scientists in human and veterinary medicine, dentistry, basic and applied sciences, engineering, and law and ethics. The journal is dedicated to the publication of outstanding articles of interest to the surgical research community.